HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hyperhomocysteinaemia in chronic liver diseases: role of disease stage, vitamin status and methylenetetrahydrofolate reductase genetics.

AbstractBACKGROUND/AIMS:
The liver plays a key role in sulphur aminoacid metabolism hence, homocysteine metabolism may be impaired in chronic liver diseases. The aim of this study was to investigate, in patients affected by chronic liver diseases, (1) the prevalence of hyperhomocysteinaemia and (2) the role of its determinants such as the stage and the aetiology of disease, vitamin status, genetic documented alterations (methylenetetrahydrofolate reductase deficiency) and presence/absence of documented malignant evolution (hepatocellular carcinoma).
MATERIAL AND METHODS:
One hundred and thirty patients with chronic liver disease (34 with chronic active hepatitis, 12 with fatty liver and 88 with liver cirrhosis) and 50 healthy age-matched control subjects were included into the study.
RESULTS:
Hyperhomocysteinaemia was defined as homocysteine plasma levels greater than 12.6 micromol/l. Hyperhomocysteinaemia prevalence in liver cirrhosis group was 40.9%, significantly higher (all P<0.01) with respect to controls (12%), chronic active hepatitis (14.7%) and fatty liver (25%) groups and increased with Child-Pugh stage [Child A: 22.2%, Child B (50%); Child C (58.3%)]. In chronic-active hepatitis and liver cirrhosis, the prevalence of subjects with methylenetetrahydrofolate reductase C677-->T mutation (both as CT and as TT) and hyperhomocysteinaemia results in significantly higher levels with respect to controls. Methylenetetrahydrofolate reductase C677-->T mutation and disease stage showed to be the most important predictive factors of hyperhomocysteinaemia in liver cirrhosis whereas the influence of homocysteine-related vitamin status seems to have a secondary role.
CONCLUSIONS:
In conclusion hyperhomocysteinaemia is highly prevalent in liver cirrhosis but not in other chronic liver diseases; it may contribute to fibrogenesis and vascular complication of liver cirrhosis.
AuthorsPaolo Ventura, Maria Cristina Rosa, Gianluca Abbati, Stefano Marchini, Elvira Grandone, Patrizia Vergura, Silvia Tremosini, Maria Luisa Zeneroli
JournalLiver international : official journal of the International Association for the Study of the Liver (Liver Int) Vol. 25 Issue 1 Pg. 49-56 (Feb 2005) ISSN: 1478-3223 [Print] United States
PMID15698398 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Methylenetetrahydrofolate Reductase (NADPH2)
Topics
  • Avitaminosis
  • Carcinoma, Hepatocellular (complications, enzymology, pathology)
  • Chronic Disease
  • Fatty Liver (complications, enzymology, pathology)
  • Genetic Predisposition to Disease
  • Hepatitis, Chronic (complications, enzymology, pathology)
  • Humans
  • Hyperhomocysteinemia (complications, enzymology, pathology)
  • Liver Cirrhosis (complications, enzymology, pathology)
  • Liver Diseases (complications, enzymology, pathology)
  • Liver Neoplasms (complications, enzymology, pathology)
  • Methylenetetrahydrofolate Reductase (NADPH2) (genetics)
  • Mutation, Missense
  • Point Mutation

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: